Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 11/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209020 | 1.00 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3869797 | 1.00 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14201555 | 0.92 | CTSB (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8364910 | 0.87 | BACE1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3877669 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3877670 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5446725 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8365430 | 0.83 | BACE1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4799325 | 0.81 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8126305 | 0.81 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557137-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-15 | — | — | US | disclosed |
| EP-1551801-A4 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1551801-A1 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004013098-A1 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, APP, BACE2 | PSEN1 4/4885PSEN2 9/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.